

ZACKS RESEARCH SYSTEM 5.0

THE COMPLETE SYSTEM FOR MANAGING U.S. EQUITIES

ALL THE REPORTS, DISPLAYS, AND TOOLS YOU NEED TO MANAGE A U.S. EQUITY PROCESS

- ▶ **Daily Focus List Report** produce the daily report used by portfolio managers to monitor changing financial ratios for their investment universe
- ▶ **Screening** screen from a universe of over 8,000 stocks using 600 pre-defined items or your own custom calculations
- ▶ **Backtesting** test your theories by simulating investment performance under specific trading conditions
- ▶ **Portfolio Analytics/Performance Attribution** evaluate & manage portfolios, comparing the performance and financial characteristics to benchmarks, including performance attribution
- ▶ **Zacks Excel Link** use Zacks data to seamlessly create custom spreadsheets and reports in Microsoft Excel for internal use or client presentations
- ▶ **Events Calendar/Transcripts** stay on top of the latest company and economic events including transcripts of earnings calls
- ▶ **Integrated Charts and News** easily view the news stories that have impacted stock prices recently to assess company price sensitivity
- ▶ **Company Snapshot** one-page quantitative report highlighting technical factors on a company

Easily Create Customizable Portfolio Characteristics, Performance Attribution, And Single Company Reports

Posted	Published	Ticker	Company	Broker	Analyst	Fmt	Pgs	Type
9/19/2008 3:40:21 AM	9/19/2008	MRK	MERCK & CO INC	Black Box Investing		PDF	18	Company Report
9/19/2008 3:44:29 PM	9/19/2008	MRK	MERCK & CO INC	Desjardins Securities		PDF	5	Industry Report
9/19/2008 10:15:01 AM	9/19/2008	MRK	MERCK & CO INC	Desjardins Securities		PDF	12	Industry Report
7/24/2008 2:50:50 PM	7/23/2008	MRK	MERCK & CO INC	Leerink Swann & Co.	S FERNANDEZ	PDF	12	Company Report
7/23/2008 4:00:04 AM	7/23/2008	MRK	MERCK & CO INC	Hillard Lyons	S O'NEIL	PDF	6	Company Report
7/22/2008 2:14:59 PM	7/22/2008	MRK	MERCK & CO INC	Leerink Swann & Co.	S FERNANDEZ	PDF	12	Company Report
7/22/2008 8:04:58 AM	7/22/2008	MRK	MERCK & CO INC	Zacks Investment Research	J NAIPODANO	PDF	2	Company Report
7/22/2008 4:17:00 AM	7/21/2008	MRK	MERCK & CO INC	Company Press Release		PDF	15	Company Report
7/21/2008 2:45:01 PM	7/21/2008	MRK	MERCK & CO INC	Leerink Swann & Co.	S FERNANDEZ	PDF	7	Company Report
7/21/2008 2:45:01 PM	7/21/2008	MRK	MERCK & CO INC	Leerink Swann & Co.	S FERNANDEZ	PDF	12	Company Report

Full-Text Reports Delivered To Your Desktop

RESEARCH DELIVERY PLUS STREAMLINED CONSENSUS SUMMARIES

- ▶ **Research Delivery** access full-text research reports from over 180 contributing sell-side brokerage firms
- ▶ **Zacks Research Digest** consolidates all the sell-side research on a company into one easy to read consensus report and model, saving you the task of reading through redundant reports
- ▶ **Consensus Company Model** historical income statement, balance sheet, and cash flows are extended into the future using consensus forecasts of individual line items
- ▶ **Consensus Comparative Business Segment Revenue** comparative consensus forecasts of revenue at the business segment and product level in 25 industries

	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	26,987.00	22,636.00	22,915.00	22,408.00	21,782.00	21,275.00	20,770.00	20,265.00
Cost of sales	8,140.70	8,001.50	5,149.80	4,859.80	4,315.30	3,303.60	2,876.50	2,456.40
Research and development	4,832.80	4,782.00	3,848.00	4,010.00	3,776.30	3,077.20	2,456.40	2,456.40
Acquired research	101.30	101.30	101.30	101.30	101.30	101.30	101.30	101.30
Marketing and administrative	7,056.70	6,155.40	7,100.00	7,340.30	6,384.90	6,180.00	6,224.40	6,224.40
Restructuring costs	307.10	142.00	302.00	—	—	—	—	—
U.S. Visa Settlement Agreement charge	4,859.00	—	—	—	—	—	—	—
Equity income from affiliates	2,976.50	2,284.40	1,717.10	1,008.20	474.20	544.70	685.00	—
Interest expense	744.10	754.30	490.90	473.40	404.90	419.30	490.50	—
Income from continuing operations before taxes	3,370.70	6,221.40	7,363.80	7,874.50	8,051.60	10,213.00	10,482.60	—
Deferred provision Federal	368.10	1,816.40	1,846.10	1,409.00	1,644.00	1,684.60	1,680.40	—
Deferred provision State	202.20	241.10	295.00	161.30	254.80	348.40	325.80	—
Deferred provision Foreign	607.00	408.30	739.00	200.00	611.30	600.30	620.70	—
Income tax expense	95.30	1,787.60	2,732.60	2,161.10	2,462.00	3,064.10	3,120.80	—
Income from continuing operations, net of taxes	—	4,433.80	4,631.20	5,713.40	5,589.60	7,148.90	7,281.80	—
Net income	3,275.40	4,433.80	4,631.20	5,713.40	5,589.60	7,148.90	7,281.80	—
Basic Earnings per Common Share Continuing Operations	—	2.11	2.02	2.05	2.05	2.31	2.31	—
Basic Earnings per Common Share Discontinued Operations	—	—	—	—	—	—	—	—
Net Earnings Per Share (Basic)	1.51	2.04	2.11	2.02	2.05	2.31	2.31	—
Earnings per Common Share Assuming Dilution Continuing Operations	—	—	—	—	—	—	—	—
Earnings per Common Share Assuming Dilution Discontinued Operations	—	—	—	—	—	—	—	—
Net Earnings Per Share (Diluted)	1.48	2.03	2.10	2.01	2.01	2.31	2.31	—
Average common shares outstanding	2,170.80	2,177.80	2,187.00	2,218.00	2,218.70	2,267.50	2,268.30	—
Average common shares outstanding assuming dilution	2,192.00	2,188.70	2,200.40	2,225.40	2,225.10	2,277.00	2,272.30	—

Easily Compare Company Financial Statements in Standardized or As-Reported Formats

ALL THE PUBLIC INFO YOU NEED ON YOUR DESKTOP

- ▶ **Estimates** view detailed and consensus estimates, as well as, surprise momentum and revisions history
- ▶ **Company Fundamentals** click through standardized and as-reported company financial statements for 8,000 U.S. and Canadian companies, ADRs, and ETFs
- ▶ **Prices** near real-time, daily, 20 years of history
- ▶ **Institutional Data** institutional holdings and insider transactions

FURTHER INCREASE YOUR PERFORMANCE WITH ZACKS PROPRIETARY RESEARCH

Zacks Independent Research broad research coverage of large-caps, mid-caps, small-caps, and ADRs produced by 50 person equity research department

Zacks Quant Model Predicts Relative Returns For Next Quarter the Zacks Rank # 1 stocks have delivered 30% annualized returns over the last 25 years

Zacks Quant Model Predicts Surprises Zacks PRI model successfully predicts surprises and price response to surprises

Industry	Revenue (\$mm)	Net Income (\$mm)
DRUGS	24,191	4,952
MRK	8,625	7,525

Valuation	MRK	Ind	Q10-4 Gr	As of	MRK	Ind	MRK	Ind
P/E (ttm)	10.82	21.21	—	Jun-2008	-1.0%	8.8%	4.9%	9.1%
P/E F1	10.81	20.48	—	Jun-2008	-1.0%	8.8%	4.9%	9.1%
P/ECE	13.14	18.71	—	Sep-2008	-0.2%	14.9%	4.0%	5.8%
P/Book	3.78	3.19	Y1-1 Gr	Fiscal Yr	—	—	—	—
P/Sales	3.17	5.62	—	Dec-2007	8.9%	14.9%	27.0%	13.3%
EV/EBITDA	9.82	12.85	—	Dec-2008	-0.3%	15.9%	3.1%	8.4%
Margin (ttm)	—	—	—	Dec-2008	4.6%	20.8%	8.8%	15.8%
Pre-Tax	22.1%	-10.0%	LT Gr	As of	—	—	—	—
Op. Mgn	29.6%	-56.1%	Last 5 yr	Jun-2008	1.3%	14.0%	1.4%	17.0%
Net	20.5%	-83.0%	Est 3-5 yr	Aug-2008	6.2%	19.8%	—	—



Home View with Customizable Metrics and Charts

CUSTOMIZE ZRS 5.0 TO MATCH YOUR DECISION PROCESS

- ▶ **Customized Home Page** organize your home page with the information you want displayed to help you make better stock selection decisions
- ▶ **Custom Metrics** ZRS 5.0 can incorporate and display any custom valuation metrics you use to make investment decisions
- ▶ **Custom Analytics** ZRS 5.0's analytics are based on relative comparisons to your custom peer and industry groups
- ▶ **Customizable Charts and Graphs** view and export easily to add graphics to company reports

FOR MORE INFORMATION PLEASE CONTACT YOUR ZACKS REPRESENTATIVE OR NICK ANASTASIA AT 312-265-9249 (EMAIL: NANASTASIA@ZACKS.COM).